128 related articles for article (PubMed ID: 14967453)
1. The HER receptor family: a rich target for therapeutic development.
Mass RD
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):932-40. PubMed ID: 14967453
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Langer CJ
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):991-1002. PubMed ID: 14967461
[TBL] [Abstract][Full Text] [Related]
3. New insights into anti-HER-2 receptor monoclonal antibody research.
Kumar R; Mandal M; Vadlamudi R
Semin Oncol; 2000 Dec; 27(6 Suppl 11):84-91; discussion 92-100. PubMed ID: 11236033
[TBL] [Abstract][Full Text] [Related]
4. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
5. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor inhibitors in clinical development.
Dancey J
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):1003-7. PubMed ID: 14967462
[TBL] [Abstract][Full Text] [Related]
7. 2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth.
Takai N; Jain A; Kawamata N; Popoviciu LM; Said JW; Whittaker S; Miyakawa I; Agus DB; Koeffler HP
Cancer; 2005 Dec; 104(12):2701-8. PubMed ID: 16265675
[TBL] [Abstract][Full Text] [Related]
8. Anti-HER therapeutic agents in the treatment of non-small-cell lung cancer.
Krawczyk P; Chocholska S; Milanowski J
Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):113-7. PubMed ID: 15314969
[TBL] [Abstract][Full Text] [Related]
9. Blockade of the HER family of receptors in the treatment of HER2-positive metastatic breast cancer.
Sachdev JC; Jahanzeb M
Clin Breast Cancer; 2012 Feb; 12(1):19-29. PubMed ID: 21903480
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4.
Albanell J; Codony J; Rovira A; Mellado B; Gascón P
Adv Exp Med Biol; 2003; 532():253-68. PubMed ID: 12908564
[TBL] [Abstract][Full Text] [Related]
12. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.
Nahta R; O'Regan RM
Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer.
Herbst RS; Johnson DH; Mininberg E; Carbone DP; Henderson T; Kim ES; Blumenschein G; Lee JJ; Liu DD; Truong MT; Hong WK; Tran H; Tsao A; Xie D; Ramies DA; Mass R; Seshagiri S; Eberhard DA; Kelley SK; Sandler A
J Clin Oncol; 2005 Apr; 23(11):2544-55. PubMed ID: 15753462
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
Medina PJ; Goodin S
Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
[TBL] [Abstract][Full Text] [Related]
15. HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors.
Nielsen DL; Andersson M; Kamby C
Cancer Treat Rev; 2009 Apr; 35(2):121-36. PubMed ID: 19008049
[TBL] [Abstract][Full Text] [Related]
16. New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.
Doebele RC; Oton AB; Peled N; Camidge DR; Bunn PA
Lung Cancer; 2010 Jul; 69(1):1-12. PubMed ID: 20092908
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase.
Rabindran SK; Discafani CM; Rosfjord EC; Baxter M; Floyd MB; Golas J; Hallett WA; Johnson BD; Nilakantan R; Overbeek E; Reich MF; Shen R; Shi X; Tsou HR; Wang YF; Wissner A
Cancer Res; 2004 Jun; 64(11):3958-65. PubMed ID: 15173008
[TBL] [Abstract][Full Text] [Related]
18. ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Saxena R; Dwivedi A
Med Res Rev; 2012 Jan; 32(1):166-215. PubMed ID: 22183797
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
[TBL] [Abstract][Full Text] [Related]
20. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
